ArticleJournal of thoracic disease2025
Bayesian-weighted Mendelian randomization reveals sleep apnea syndrome mediates the BMI-chronic pain link.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Body mass index (BMI) has a complex association with a variety of chronic pain conditions, which may be influenced by sleep apnea syndrome (SAS). However, the role of SAS within the causal pathway linking BMI to chronic pain remains unconfirmed. This study explored whether and to what extent SAS serves as a mediator between BMI and chronic pain using Bayesian-weighted Mendelian randomization (BWMR) techniques. Methods: This study utilized genome-wide association study (GWAS) summary data for BMI (N=461,460) and SAS (N=476,853; based on ICD-10 code diagnostic registries) from the IEU OpenGWAS database, along with chronic pain GWAS data (ICD-10 code-based diagnostic registries) from the FinnGen database. Utilizing BWMR and inverse-variance weighted (IVW) methods, a two-step, two-sample Mendelian randomization (MR) design was employed to investigate the causal relationships between BMI and various types of chronic pain and to assess the mediating role of SAS in the BMI-chronic pain link. Additionally, a suite of sensitivity analyses, including the use of MR-PRESSO to remove outliers, MR-Egger regression to assess horizontal pleiotropy, and Cochran's Q test to evaluate heterogeneity, thereby ensuring the robustness and reliability of the MR study findings. Results: The GWAS data for BMI, SAS, and chronic pain were all derived from European populations, comprising 9,851,867 BMI-associated single-nucleotide polymorphisms (SNPs), 24,183,940 SAS-related SNPs, and 19,680,346 to 19,682,705 chronic pain-linked SNPs in the respective datasets. BWMR revealed significant genetic associations between BMI and various types of chronic pain, including limb pain [odds ratio (OR) =1.34, 95% confidence interval (CI): 1.25-1.44, P<0.001], low back pain (OR =1.34, 95% CI: 1.25-1.43, P<0.001), low back pain with or without sciatica (OR =1.28, 95% CI: 1.21-1.36, P<0.001), and thoracic spine pain (OR =1.18, 95% CI: 1.03-1.36, P=0.02). Additionally, the genetic predisposition of BMI was also strongly associated with the risk of SAS (OR =2.34, 95% CI: 2.12-2.59, P<0.001). Mediation analysis revealed that SAS mediated 15.3% (β=0.045) of BMI's causal effect on limb pain, 26.8% (β=0.078) on low back pain, and 26.8% (β=0.067) on low back pain with or without sciatica. Conclusions: There is a causal relationship between BMI and chronic pain, with SAS acting as a mediator for a portion of the causal effects of BMI on conditions such as limb pain, low back pain, and low back pain with or without sciatica. Therefore, clinical strategies should focus on modulating BMI levels to maintain them within the normal range, which may effectively reduce the incidence risk of chronic pain. Furthermore, in patients with elevated BMI and comorbid SAS, targeted SAS treatment could potentially mitigate BMI-associated chronic pain burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.